1. Dolin R, Morg J. Antiviral Agents: General Principles Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, Ninth Edition, Elsevier Inc. 2020; pp:556-559.
2. Aoki FY. Antivirals Against Herpesviruses Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, Ninth Edition, Elsevier Inc. 2020; pp:577-595.
3. Razonable Rr. Antiviral drugs for viruses other than human immunodeficiency virus Mayo Clin Proc 2011;86:1009-1026.
4. Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010; 304:859.
5. Polso AK, Lassiter JL, Nagel JL. Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review. J Clin Pharm Ther 2014;
39:584.
6. Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol 2010; 49:151.
7. Venturi C, Bueno J, Gavalda J, et al. Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report. Transplant Proc 2009;
41:1038.
8. Limaye AP, Budde K, Humar A, et al. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA.
2023;330(1):33-42
9. Chan KKP, Hui DSC. Antiviral therapies for influenza. Curr Opin Infect Dis 2023;36:124-131
10. Lytras T, Mouratidou E, Andreopoulou A, et al. Effect of Early Oseltamivir Treatment on Mortality in Critically Ill Patients With Different Types of Influenza: A Multiseason Cohort Study.
Clin Infect Dis 2019; 69:1896.
11. Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus
infection. Antimicrob Agents Chemother 2011; 55:5267.
12. Chen HD, Wang X, Yu SL, et al. Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia: A Rando-
mized Controlled Study. Open Forum Infect Dis 2021; 8:ofaa562.
13. Ergönül Ö. Crimian Congo Haemorhagic Fever. Lancet Infect Dis 2006;6(4):203-214.
14. Interim Clinical Considerations for COVID-19 Treatment in Outpatients https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/outpatient-treatment-overview.html Updated Jan.
17, 2024https://www.covid19treatmentguidelines.nih.gov/ Last Updated: December 20, 2023
15. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines https://www.covid19treatmentguidelines.nih.gov/ Last Updated: December 20, 2023
16. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10:1.
17. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the
management of hepatitis B virus infection. J Hepatol 2017; 67:370.
18. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67:1560.
19. Demirtürk N et al. KHB Takibi: Uzlaşı RaporuKronik Hepatit B İnfeksiyonunun Yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu Uzlaşı
Raporu-2023 Klimik Dergisi 2023; 36(Özel Sayı 1): 1-22
20. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017; 66:153.
21. Bhattacharya D, Aronsohn A, Price J, et al. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect
Dis 2023.
22. Aygen B et al. Kronik Hepatit C Virusu İnfeksiyonunun Yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu Uzlaşı Raporu-2023 Güncelle-
mesi Klimik Dergisi 2023; 36(Özel Sayı 1): 43-75
23. Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015; 373:2599.
24. Mangia A, Milligan S, Khalili M, et al. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. Liver Int 2020;
40:1841
25. Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol
2018; 69:293.
26. Lampertico P, Carrión JA, Curry M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. J Hepatol
2020; 72:1112.
27. Negro F, Lok ASF.Treatment and prevention of hepatitis D virus infection https://www.uptodate.com/contents/treatment-and-prevention-of-hepatitis-d-virus-infection 18 October 2023
Update.
28. Dolin R, Walsh SR. Miscellaneous Antiviral Agents (Interferons, Tecovirimat, Imiquimod, Pocapavir, Pleconaril) General Principles Mandell, Douglas, and Bennett’s Principles and Practice
of Infectious Diseases, Ninth Edition, Elsevier Inc. 2020; pp:620-627.
29. Hanna GJ, Hirsch MS. Antiretro viral therapy for Human Immunodeficiency Virus Infection. In: Mandell GL, Bennett JE, Dolin R (eds). Principles and Practice of Infectious Diseases. New
York, Churchill Livingstone, 2005, pp:1655-1677.
30. Tsibris AMN, Hirsch MS. Antiretroviral Therapy for Human Immunodeficiency Virus Infection. In: Mandell GL, Bennett JE, Dolin R (eds). Principles and Practice of Infectious Diseases.
New York, Churchill Livingstone, 2010 pp:1833-1853.
31. Tsibris AMN, Hirsch MS. Antiretroviral Therapy for Human Immunodeficiency Virus Infection. In: Mandell GL, Bennett JE, Dolin R, Blaser MJ (eds). Principles and Practice of Infectious
Diseases. Philadelphia, Elsevier,2020 pp:1739-1760.
32. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv (Erişim tarihi: 01.03.2024)
33. https://www.eacsociety.org/media/guidelines-12.0.pdf (Erişim tarihi: 01.03.2024)
34. Tavel JA, Miller KD, Masur H. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus – infected patients: Protease inhibitors, non-nucleosid reverse transc-
riptase inhibitors, and nucleotide reverse transcriptase inhibitors. Clin Infec Dis 1999; 28:643-676.
35. Stockdale AJ, Khoo S. Doravirine: its role in HIV treatment Curr Opin HIV AIDS 2022;17(1):4-14.
36. Kasper DL, Braunwald E, Fauci AS. HIV infection and AIDS. Harrison’s manual of medicine Blacklick OH, USA, McGraw- Hill Companies 2005, pp:424-454.
37. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection. JAMA 2006;296:823-843.
38. Tavel JA, Miller KD, Masur H. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus – infected patients: Protease inhibitors, non-nucleosid reverse transc-
riptase inhibitors, and nucleotide reverse transcriptase inhibitors. Clin Infec Dis 1999; 28:643-676.
39. Emu B, Fessel J, Schrader S, et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med. 2018;379(7):645-654.
40. Lagishetty C, Moore K, Ackerman P, Llamoso C, Magee M. Effects of temsavir, active moiety of antiretroviral agent fostemsavir, on QT interval: results from a Phase I study and an exposu-
re-responses analysis. Clin Transl Sci. 2020;13(4):769-776.
41. Prather C, Lee A, Yen C, Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV, American Journal of Health-System Pharmacy, 2023;80(24):
1774–1780
42. Patel P, Teichner P, Elliot E, et al. Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine. Ther Adv Infect Dis. 2023 Dec
13;10:20499361231214626.